Liquid biopsy, Lung cancer screening, Smoking cessation, Locally advanced NSCLC, Early-stage NSCLC, Adjuvant therapy, Mesothelioma, Squamous cell carcinoma, Thymic tumors, The new staging system, Advanced NSCLC, Supportive therapy, Biomarkers and targeted therapy, Immunotherapy
Corey J. Langer, MD, FACP, Director of Thoracic Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
This event offers
12.5 CME credits
CE accredited by NACCME and Imedex.
Interested In Attending This Event?
Additional Registration Information:
USE CODE "PA50" AT CHECKOUT FOR $50 OFF REGISTRATION.
For 24 years, this premier gathering of healthcare professionals involved in the treatment of lung cancer continues to differentiate itself from other meetings in the field of thoracic oncology by offering a broad scope of topics essential for practicing oncologists and clinicians. The conference offers a comprehensive update on lung cancer screening and smoking cessation, biomarker testing, management of lung cancer across the spectrum of disease stages, and NSCLC, SCLC, mesothelioma, and thoracic tumors.
Join us for an unparalleled learning experience offering significant developments in the field of thoracic oncology.